一、关于公司对集团财务公司的风险持续评估报告 （一）集团财务公司作为非银行金融机构，其业务范围、 业务流程、内部的风险控制制度都受到中国银保监会的严格 监管。我们未发现集团财务公司的风险管理存在重大缺陷， 公司与其之间的关联存贷款业务风险可控。公司的查验程序 合理、合法，风险评估充分、完备，本风险评估报告客观公 正。 （二）本次董事会对风险评估报告的表决程序符合相关 规定，关联董事回避了表决, 体现了公开、公平、公正的原 则，符合《公司法》及《公司章程》的规定,表决程序合法 有效。 据此，我们同意风险持续评估报告。 二、关于提名独立董事候选人的议案 中国医药健康产业股份有限公司 独立董事对公司第九届董事会第 7 次会议审议相关事项的 独立意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）《上 市公司证券发行管理办法》《上市公司独立董事管理办法》 《上海证券交易所股票上市规则》和《中国医药健康产业股 份有限公司章程》（以下简称"《公司章程》"）等有关规 定，我们作为中国医药健康产业股份有限公司（以下简称"公 司"）独立董事，就公司第九届董事会第 7 ...

一、本人具备上市公司运作的基本知识，熟悉相关法律、行 政法规、部门规章及其他规范性文件，具有 5 年以上法律、经济、 会计、财务、管理或者其他履行独立董事职责所必需的工作经验。 本人尚未参加培训并取得证券交易所认可的相关培训证明 材料。本人承诺，在本次提名后，参加上海证券交易所举办的最 近一期独立董事任前培训并取得相关培训证明。 二、本人任职资格符合下列法律、行政法规和部门规章以及 公司规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的 规定； （三）中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定； 独立董事候选人声明与承诺 本人闫永红，已充分了解并同意由提名人中国医药健康产业 股份有限公司董事会提名为中国医药健康产业股份有限公司第 九届董事会独立董事候选人。本人公开声明，本人具备独立董事 任职资格，保证不存在任何影响本人担任中国医药健康产业股份 有限公司独立董事独立性的关系，具体声明并承诺如下： （四）中共中央纪委、中共中央组织部《关于规范中管干部 辞去公职或者退（ ...

中国医药健康产业股份有限公司 关联交易管理制度 （2023 年 8 月修订） 第一章 总 则 第一条 为了规范中国医药健康产业股份有限公司（以下简 称"公司"）的关联交易行为，保证公司与关联方所发生关联交 易的合法性、公允性、合理性，充分保障股东、特别是中小股东 和公司的合法权益，依据《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司治理准则》《企业会计准则第 36 号—— 关联方披露》《上海证券交易所股票上市规则》（以下简称"《股 票上市规则》"）《上海证券交易所上市公司自律监管指引第 5 号 ——交易与关联交易》和《公司章程》等有关规定，制定本制度。 第二章 关联人界定 第二条 公司的关联人包括关联法人（或者其他组织）和关 联自然人： （一）具有以下情形之一的法人（或者其他组织），为公司 的关联法人（或者其他组织）： 1、直接或者间接控制公司的法人（或者其他组织）； 2、由前项所述法人（或者其他组织）直接或者间接控制的 除公司、控股子公司及控制的其他主体以外的法人（或者其他组 织）； 3、由本条（二）所列公司的关联自然人直接或者间接控制 的，或者由关联自然人担任董事（不含同为双方的独立董事）、 ...

中国医药健康产业股份有限公司 董事会薪酬与考核委员会实施细则 （2023 年 8 月修订） 第一章 总 则 第一条 为进一步建立健全中国医药健康产业股份有限公 司（以下简称"公司"）董事（非独立董事）及高级管理人员的 考核和薪酬管理制度，完善公司治理结构，根据《中华人民共和 国公司法》《上市公司治理准则》《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 《公司章程》及其他有关规定，公司设立董事会薪酬与考核委员 会，并制定本实施细则。 第二条 薪酬与考核委员会是董事会按照股东大会决议设 立的专门工作机构，对董事会负责。主要负责制定公司董事及高 级管理人员的考核标准并进行考核；负责制定、审查公司董事及 高级管理人员的薪酬政策与方案。 第三条 本实施细则所称董事是指在本公司领取薪酬的董 事，高级管理人员是指董事会聘任的总经理、副总经理、董事会 秘书、总会计师及由公司章程认定的其他高级管理人员。 第二章 人员组成 第四条 薪酬与考核委员会成员由三名董事组成，独立董事 占多数。 第五条 薪酬与考核委员会委员由董事长、二分之一以上独 立董事或者全体董事的三分之一提名，并由董事会 ...

Financial Performance - The company's operating revenue for Q1 2023 reached ¥12,530,663,199.18, representing a year-on-year increase of 47.08%[6] - Net profit attributable to shareholders of the listed company was ¥268,770,140.93, reflecting a growth of 9.27% compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses was ¥252,398,608.34, which is an increase of 16.81% year-on-year[6] - The basic earnings per share for the period was ¥0.1797, up by 9.31% from the previous year[6] - Total revenue for Q1 2023 reached ¥12,530,663,199.18, a significant increase of 47.3% compared to ¥8,519,901,885.91 in Q1 2022[50] - Net profit for Q1 2023 was ¥320,582,342.33, compared to ¥300,838,706.54 in Q1 2022, indicating a growth of 6.5%[52] - Total comprehensive income for Q1 2023 reached CNY 320,807,864.51, compared to CNY 300,838,706.54 in Q1 2022, reflecting an increase of approximately 6.5%[53] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥38,610,045,123.38, marking a 7.55% increase from the end of the previous year[6] - The total assets as of March 31, 2023, amounted to ¥38,610,045,123.38, up from ¥35,898,612,572.08 at the end of 2022, showing a growth of 7.5%[50] - The total liabilities as of March 31, 2023, were ¥25,116,046,768.68, compared to ¥22,725,525,501.42 at the end of 2022, an increase of 10.5%[50] - The equity attributable to shareholders increased to ¥11,084,871,359.58 from ¥10,815,778,221.23, reflecting a growth of 2.5%[50] Cash Flow - The net cash flow from operating activities was negative at -¥1,491,826,630.90, indicating a significant cash outflow during the quarter[6] - Net cash flow from operating activities for Q1 2023 was -CNY 1,491,826,630.90, compared to -CNY 901,941,859.28 in Q1 2022, indicating a decline in cash flow[55] - Cash inflow from financing activities in Q1 2023 was CNY 3,007,281,481.92, significantly higher than CNY 1,305,000,000.00 in Q1 2022, reflecting an increase of approximately 130.5%[56] - The company reported a net increase in cash and cash equivalents of -CNY 1,373,200,424.42 in Q1 2023, compared to -CNY 412,753,278.60 in Q1 2022, indicating a worsening cash position[56] Operational Highlights - Operating revenue increased by 47.08% due to growth in pharmaceutical and medical device sales[26] - Research and development expenses rose by 84.91% reflecting increased investment in R&D[26] - Cash received from sales of goods and services increased by 42.02% indicating higher cash inflow from sales[26] - Long-term receivables decreased by 39.56% as a result of recovering some long-term receivables[26] - Other current assets increased by 121.67% due to an increase in deductible input tax[26] - The company reported a 204.87% increase in asset impairment losses, primarily due to increased inventory write-downs[26] - Cash paid for purchasing fixed assets increased by 124.21% indicating higher capital expenditures[26] - The company’s short-term borrowings increased by 84.08% as it repaid borrowings due within one year[26] - Other income decreased by 69.33% due to a reduction in government subsidies received[26] - The company’s cash received from tax refunds increased by 73.48% reflecting higher export tax rebates[26] Investment and Financial Instruments - The company reported a significant increase of 669.80% in derivative financial assets due to an increase in forward contracts[24] - The company reported a significant increase in investment income to ¥15,302,950.13 in Q1 2023, compared to a loss of ¥47,643.81 in Q1 2022[52]

Financial Performance - The company achieved operating revenue of CNY 37.59 billion in 2022, a year-on-year increase of 3.75%[11] - Operating costs rose to CNY 32.85 billion, reflecting a year-on-year increase of 5.89%[3] - The gross profit margin for the main business was 12.53%, a decrease of 1.72 percentage points compared to the previous year[11] - Net profit attributable to shareholders reached CNY 735.71 million, an increase of 13.70% compared to the previous year[115] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 599.77 million, up 2.56% year-on-year[116] - Total assets at the end of 2022 amounted to CNY 35.90 billion, reflecting a year-on-year increase of 15.39%[115] - The company's net assets attributable to shareholders were CNY 10.82 billion, up 5.44% from the previous year[115] - The company achieved a revenue of 37.593 billion RMB, representing a year-on-year growth of 3.75%[145] - Net profit attributable to shareholders reached 736 million RMB, with a year-on-year increase of 13.70%[145] Cash Flow and Investments - The net cash flow from operating activities reached CNY 1.65 billion, a significant increase of 1,008.92% year-on-year[3] - The net cash inflow from investment activities increased by 277 million yuan compared to the same period last year, mainly due to the disposal of certain assets[20] - The net cash inflow from financing activities increased by 727 million yuan compared to the same period last year, primarily due to increased cash inflow from borrowings[20] - The company's cash and cash equivalents increased by 52.21% year-on-year, amounting to approximately 4.26 billion yuan[25] - The company has maintained a strong financial position, with a cash reserve of 2 billion RMB to support future growth initiatives[163] Research and Development - Research and development expenses amounted to CNY 77.33 million, up 34.76% from the previous year[13] - The company’s R&D investment accounted for 0.54% of operating revenue, with 61.83% of R&D expenditures capitalized[13] - The company emphasized the importance of innovation-driven development and strengthened its technology innovation system[64] - The company aims to enhance its product pipeline and improve R&D precision and product competitiveness[64] - Research and development investments have increased by 30%, focusing on advanced technologies in pharmaceuticals[169] Market and Industry Trends - The company operates in the pharmaceutical manufacturing industry, which is undergoing significant reforms under the "14th Five-Year Plan" in China[34] - In 2022, the average price reduction for 67 exclusive drugs negotiated outside the directory was 61.71%[42] - The eighth round of national drug procurement resulted in an average price reduction of 56% for selected drugs[42] - The government emphasized the expansion of centralized procurement for drugs and high-value medical consumables, aiming for a unified national medical insurance drug range by the end of 2022[42] - The overall demand for hospital terminal drug sales decreased by 2.8% in 2022 due to centralized procurement and price reductions[139] Product Development and Approvals - The company received production approvals for six products, including Rosuvastatin Calcium Tablets and Acetate Atorvastatin Injection[64] - The company submitted 17 drug products for approval and received approval for 21 products during the reporting period, which is expected to positively impact future sales and market share[79] - In 2022, the company approved 8 new generic drugs and 5 new active pharmaceutical ingredients, enhancing its product pipeline[136] - The pharmaceutical manufacturing segment saw significant progress, with 21 new drug approvals and 17 registrations completed[130] Strategic Initiatives and Future Outlook - The company plans to accelerate the construction of network points in blank provinces and cities, in line with national hierarchical diagnosis and treatment policies[1] - The company is focusing on expanding its market presence and exploring innovative business models to drive high-quality growth[116] - The company is actively expanding its international trade business, establishing a subsidiary in Mexico that became profitable in its first year[130] - The company is enhancing its internal control system, improving risk identification and prevention capabilities[136] - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 12% to 15%[165] Operational Efficiency - The company is focused on cost reduction and efficiency improvement, with significant decreases in production procurement costs for key products[130] - The company plans to implement new operational strategies aimed at improving efficiency by 10% over the next year[170] - Sales expenses decreased by 11.32% year-on-year, influenced by policies such as volume-based procurement[150] - Management expenses rose by 14.18% year-on-year, primarily due to equipment investment in hospital projects and increased personnel costs[150] Corporate Governance and Management - The board of directors has undergone changes, with several key personnel adjustments aimed at strengthening leadership[165] - The company appointed Hu Huidong as the new general manager after the resignation of Wang Hongxin, effective from August 2, 2022[171] - The company approved the appointment of new deputy general managers and a general manager assistant during the board meeting on August 2, 2022[171] - The company discussed the transfer of its controlling subsidiary Shanghai Xinxing Co. during the board meeting on November 18, 2022[174] Employee and Workforce Management - The total number of employees in the parent company is 189, while the total number of employees across the parent and major subsidiaries is 8,313[199] - The workforce consists of 3,185 production personnel, 1,934 sales personnel, 1,071 technical personnel, 455 financial personnel, 1,453 administrative personnel, and 215 other personnel[199] - The total number of employees with a master's degree or above is 409, while those with a bachelor's degree is 2,470[199]

证券代码：600056 证券简称：中国医药 公告编号：临 2023-034 号 中国医药健康产业股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2023 年 5 月 4 日(星期四) 至 5 月 10 日(星期三)16:00 前登录上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 meheco600056@meheco.gt.cn 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 中国医药健康产业股份有限公司（以下简称"公司"）于 2023 年 4 月 29 日 发布公司 2022 年度报告及 2023 年第一季度报告，为便于广大投资者更全面深入 地了解公司 2022 年度及 2023 年第一季度经营成果、财务状况，公司计划于 2023 年 5 月 11 日 下午 16:00-17:00 举行 2022 年度暨 2023 年第一季度业绩说明 ...

证券代码：600056 证券简称：中国医药 公告编号：临 2023-003 号 中国医药健康产业股份有限公司 关于子公司药品被暂停生产销售的公告 本公司及董事会全体成员保证公告内容不存在虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实、准确和完整承担个别及连带责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）从公开信息获 悉《湖北省药品监督管理局2022年下半年药品生产监督检查情况通告》和《关于 取消湖北科益药业股份有限公司生产的注射用更昔洛韦中选资格并将该企业列 入违规名单的公告》，湖北科益药业股份有限公司（以下简称"科益药业"）系 公司下属控股子公司，现将有关情况披露如下： 一、《湖北省药品监督管理局2022年下半年药品生产监督检查情况通告》及 相关基本情况 2023年1月9日，湖北省药品监督管理局发布了《2022年下半年药品生产监督 检查情况通告》（2023年 第1号）（以下简称："通告"），通告中涉及科益药业的 检查结果如下： （一）企业名称：湖北科益药业股份有限公司 "第五批国家组织药品集中采购中选结果已于2021年10月在各地启动实施。 据湖北省药监局1月9日发布的药品生产监督检查 ...

Financial Performance - The company's operating revenue for Q3 2022 was approximately ¥9.27 billion, representing a year-on-year increase of 0.71%[3] - The net profit attributable to shareholders decreased by 8.25% year-on-year, amounting to approximately ¥150.69 million[4] - Basic earnings per share (EPS) fell by 13.71% to ¥0.1007 compared to the same period last year[4] - The weighted average return on equity (ROE) decreased by 0.30 percentage points to 1.39%[4] - Total revenue for the first three quarters of 2022 reached ¥26,917,230,015.70, a slight increase from ¥26,728,052,655.98 in the same period of 2021, representing a growth of approximately 0.7%[18] - Net profit for the first three quarters of 2022 was ¥1,235,256,040.00, compared to ¥1,261,371,419.88 in the previous year, showing a decline of around 2.1%[20] - Net profit for the first three quarters of 2022 was approximately ¥938.06 million, a decrease from ¥1,012.10 million in the same period of 2021, representing a decline of about 7.3%[21] - The net profit attributable to shareholders of the parent company was approximately ¥766.71 million, down from ¥835.61 million year-over-year, reflecting a decrease of approximately 8.2%[21] - Total comprehensive income for the first three quarters of 2022 was approximately ¥937.36 million, compared to ¥1,012.02 million in the same period of 2021, indicating a decline of about 7.4%[21] - Basic earnings per share for the first three quarters of 2022 were ¥0.5126, down from ¥0.5586 in the same period of 2021, a decrease of approximately 8.2%[22] Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥31.11 billion, reflecting a year-on-year increase of 7.57%[4] - Total current assets as of September 30, 2022, are ¥24,736,681,079.60, compared to ¥22,189,094,818.06 at the end of 2021, reflecting an increase of approximately 11.5%[15] - Total assets increased to ¥33,466,034,773.57 as of September 30, 2022, up from ¥31,110,549,416.55 at the end of 2021, indicating a growth of about 7.6%[17] - Non-current liabilities totaled ¥5,576,467,968.96 as of September 30, 2022, an increase from ¥5,104,015,354.93 at the end of 2021, representing a growth of approximately 9.2%[17] - The company reported a significant increase of 739.53% in current liabilities due to an increase in short-term borrowings[8] - The company reported a significant increase in accounts payable, which rose to ¥6,751,759,304.23 from ¥5,438,351,803.64, reflecting an increase of about 24.2%[17] Cash Flow - Cash flow from operating activities showed a net inflow of approximately ¥185.04 million, a recovery from the previous year's outflow[4] - Cash flow from operating activities for the first three quarters of 2022 was approximately ¥185.04 million, a significant improvement compared to a net cash outflow of approximately ¥762.37 million in the same period of 2021[23] - Cash inflow from operating activities totaled approximately ¥27.51 billion, an increase from ¥25.90 billion year-over-year, representing a growth of about 6.2%[23] - Cash outflow from operating activities was approximately ¥27.33 billion, compared to ¥26.67 billion in the same period of 2021, indicating an increase of about 2.5%[23] - Cash flow from investing activities generated a net inflow of approximately ¥49.89 million, a recovery from a net outflow of approximately ¥150.65 million in the same period of 2021[24] - Cash flow from financing activities resulted in a net outflow of approximately ¥564.60 million, an improvement from a net outflow of approximately ¥847.25 million in the same period of 2021[24] - The ending balance of cash and cash equivalents was approximately ¥1.51 billion, an increase from ¥912.50 million year-over-year[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 217,433[10] - The largest shareholder, China General Technology (Group) Holding Limited, holds 477,424,181 shares, representing 31.92% of total shares[10] - The top ten shareholders include several state-owned enterprises, indicating a strong government influence in the company's ownership structure[10] Research and Development - Research and development expenses increased by 35.54% during the period, indicating a focus on innovation[9] - Research and development expenses for the first three quarters of 2022 were ¥48,989,827.30, up from ¥36,144,083.47 in 2021, indicating an increase of about 35.5%[20] Legal Matters - The company has reported a total of 31 contract disputes with a total judgment amount of ¥11,994,700, of which ¥9,668,700 has been recovered[14] - The company has ongoing litigation cases, including a contract dispute with Guangdong Junyuan Chenxiang Medical Equipment Co., Ltd., currently in the second instance[14] Operational Challenges - The company faced challenges from domestic COVID-19 outbreaks and reduced export business, impacting profit levels[3] - The company is actively optimizing its industrial structure and resource allocation to drive high-quality development[3]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥17.65 billion, a decrease of 3.36% compared to the same period last year[15]. - The net profit attributable to shareholders of the listed company was approximately ¥616 million, down 6.81% year-on-year[15]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥566 million, a decrease of 6.53% compared to the previous year[15]. - The net cash flow from operating activities was approximately ¥130.88 million, showing a significant improvement from a negative cash flow of approximately ¥890.99 million in the previous year[15]. - The net assets attributable to shareholders of the listed company increased by 4.11% to approximately ¥10.68 billion compared to the end of the previous year[15]. - Total assets increased by 2.34% to approximately ¥31.84 billion compared to the end of the previous year[15]. - Basic earnings per share (EPS) was 0.4118 RMB, down 6.81% compared to the same period last year[16]. - The weighted average return on equity (ROE) decreased to 5.83%, down 0.57 percentage points year-on-year[16]. - The company faced challenges due to the resurgence of COVID-19, drug procurement policies, and a decrease in export prevention business[17]. - The pharmaceutical industry experienced a revenue decline of 0.6% in the first half of 2022, with total profit down by 27.6%[21]. Operational Developments - The company is actively expanding its regional network, focusing on key provinces such as Beijing, Guangdong, and Jiangxi[21]. - The company aims to enhance its international trade capabilities, covering a wide range of products including chemical raw materials and medical devices[21]. - The company is expanding its market network, aiming to cover all provinces except Shanghai, Jiangsu, Fujian, and Guangxi, and will accelerate the establishment of new outlets[23]. - The company is focused on strengthening its supply chain and service chain as part of its "14th Five-Year Plan" implementation[24]. - The company is actively pursuing a transformation from a logistics distributor to a comprehensive supply chain service provider, enhancing its service capabilities in the SPD business[25]. - The company plans to accelerate the development of its traditional Chinese medicine business, focusing on expanding sales channels and enhancing product quality[25]. Research and Development - Research and development expenses increased by 32.58% to CNY 32.35 million, reflecting a focus on enhancing R&D capabilities[26]. - The company successfully registered 7 overseas products in the first half of 2022, expanding its international market presence[25]. - The company introduced 3 new antiviral products and collaborated with international suppliers to add 3 new raw material products[25]. - The company has made significant progress in the consistency evaluation of generic drugs, with four products successfully passing the quality and efficacy consistency evaluation[34]. Environmental Initiatives - The company has established a comprehensive environmental protection system to ensure stable and high-quality operation of pollution control facilities[53]. - The company has actively promoted green transformation in the pharmaceutical industry, focusing on energy conservation and emission reduction[60]. - The company has developed emergency response plans for environmental incidents, with no such incidents reported in the first half of 2022[56]. - The company has adhered to national and local environmental discharge standards, ensuring compliance in waste gas, waste water, and noise emissions[59]. - The company has committed to achieving carbon neutrality goals by implementing various green development initiatives[61]. Legal and Compliance Issues - The company has ongoing litigation involving a total claim amount of 3,804.72 million RMB related to a contract dispute with 惠州鼎智科技有限公司[74]. - The company has initiated 17 lawsuits related to quality disputes with a total amount of 616 million RMB and has been involved in 37 other general contract disputes totaling approximately 113.43 million RMB[71]. - The company has no non-operating fund occupation from controlling shareholders or related parties during the reporting period[69]. - The company is committed to ensuring that it will not engage in any business that may directly or indirectly compete with China Medical and its subsidiaries[66]. Shareholder Information - The total share capital increased from 1,068,485,534 shares to 1,495,879,748 shares after the distribution of cash dividends of 1.8168 RMB per 10 shares and a bonus issue of 4 shares for every 10 shares held[92]. - The total number of shareholders reached 232,519 by the end of the reporting period[94]. - China General Technology (Group) Holding Co., Ltd. is the largest shareholder, holding 477,424,181 shares, which is 31.92% of the total shares[94]. - The number of unrestricted circulating shares at the end of the reporting period was 1,495,351,478 shares, representing 99.96% of the total shares[91]. Financial Position - The total assets decreased from 713,240,567.33 to 494,033,183.23, a decline of approximately 30.7%[41]. - The company's equity attributable to shareholders increased to CNY 10,680,056,454.27 from CNY 10,258,003,170.30, representing a growth of approximately 4.13%[101]. - The total liabilities amounted to CNY 18,820,098,717.60, slightly up from CNY 18,601,090,827.83, showing a growth of about 1.18%[101]. - Cash and cash equivalents decreased to CNY 2,129,345,256.72 from CNY 2,798,930,977.04, a decline of approximately 23.93%[99]. Tax and Regulatory Compliance - The company applies the effective interest method for calculating interest on amortized cost financial assets and liabilities[138]. - The corporate income tax rates applicable to the company are 8.25%, 15%, 20%, 25%, or exempt[196]. - The company’s subsidiaries selling anti-cancer drugs can opt for a simplified VAT calculation method at a 3% rate, effective since May 1, 2018[200]. - The company’s subsidiaries are strategically positioned to leverage tax benefits, which may positively impact their overall profitability and market expansion efforts[200].